Lysogène, specialized in the development of gene therapies against severe genetic pathologies of the central nervous system, raised € 16.5 million from Sofinnova Partners, Bpifrance Investissement and Novo Seeds. This fundraising will allow Lysogène to accelerate its expansion in Europe and in the United States.

Attorney for the company: Pinot de Villechenon & Associés (Morgan Hunault-Berret – Amélie Maindron)
Attorney for the investors: Gide Loyrette Nouel (Karen Noël – Margarita Lukashova)

La Lettre Capital Finance, May 21, 2014
Cfnews.net, May 21, 2014